ZGNX Zogenix Inc.

49.63
+1.27  (+3%)
Previous Close 48.36
Open 48.88
Price To Book 4.53
Market Cap 2,111,334,794
Shares 42,541,503
Volume 656,166
Short Ratio
Av. Daily Volume 520,491

NewsSee all news

  1. Zogenix Inc (ZGNX) EVP, CFO, Treasurer & Sec. Michael P Smith Sold $750,000 of Shares
  2. Edited Transcript of ZGNX earnings conference call or presentation 6-Aug-19 8:30pm GMT
  3. Zogenix Inc (ZGNX) Q2 2019 Earnings Call Transcript
  4. Steven Cohen Charges Into Chiasma
  5. Zogenix to Release Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 6

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 completion of enrolment announced July 8, 2019 with data due 1Q 2020.
ZX008 - (Study 1601)
Lennox-Gastaut syndrome
Approved July 16, 2009.
Sumavel
Migraine
Phase 3 to be initiated by ZGNX once partner is found.
Relday
Schizophrenia
Approved October 25, 2013.
Zohydro ER
Moderate to severe pain
Refusal to file Letter (RTF) issued April 8, 2019. Intends to resubmit NDA in September 2019.
FINTEPLA (ZX008)
Dravet syndrom
Approved January 30, 2015.
Abuse deterrent formulations of Zohydro ER
Moderate to severe pain

Latest News

  1. Zogenix Inc (ZGNX) EVP, CFO, Treasurer & Sec. Michael P Smith Sold $750,000 of Shares
  2. Edited Transcript of ZGNX earnings conference call or presentation 6-Aug-19 8:30pm GMT
  3. Zogenix Inc (ZGNX) Q2 2019 Earnings Call Transcript
  4. Steven Cohen Charges Into Chiasma
  5. Zogenix to Release Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 6
  6. How this East Bay biotech moved from an 'error' to a potential treatment for kids with severe seizures
  7. Is Zogenix, Inc. (NASDAQ:ZGNX) A Financially Strong Company?
  8. Here's Why Zogenix Leaped 26.8% in June
  9. Zogenix Completes Enrollment in Phase 3 Trial of FINTEPLA® in Lennox-Gastaut Syndrome
  10. 3 Hot Biotechs Trending Now
  11. Zogenix Inc (ZGNX) President and CEO Stephen J Farr Sold $1.6 million of Shares
  12. Can This Biotech Stock Rival The First FDA-Approved Cannabis Medicine?
  13. Here's Why Zogenix Shares Rose as Much as 23.8% Today
  14. Zogenix Secures FDA Approval For Resubmission Of Seizure Drug Application
  15. Zogenix Announces FDA Agreement to Proceed with Resubmission of FINTEPLA® NDA
  16. Zogenix, Inc.'s (NASDAQ:ZGNX) Shift From Loss To Profit
  17. Hedge Funds Have Never Been More Bullish On Zogenix, Inc. (ZGNX)
  18. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of EB, BE and ZGNX
  19. Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zogenix, Inc.
  20. The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ZGNX, XENT and CYH